Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Jimenez-Fonseca P, Valdes N, Fernandez del Valle A, Miguel C, Lauret M,
Keywords: committee, decision-making process, multidisciplinary, tool, treatment,
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Jimenez-Fonseca P, Solis Hernandez M, Fernandez del Valle A, Garcia-Carbonero R, Matos I,
Keywords: PNET, sunitinib, dose-intensive, progression-free survival,
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,
Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,
Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,